Patients with ophiasis may be categorized into 3 distinct subtypes that can guide early intervention and stratify treatment.

An FDA advisory panel will meet in late July to consider allowing 7 peptides to be used by compounding pharmacies.

Bimekizumab demonstrated a consistent safety profile across patients with PsA or axSpA in an integrated safety analysis, with the drug showing long-term tolerability.

Patients with rosacea who experience burning reported that winter months, significant temperature chances, and dietary habits trigger burning.

Close to 90% of adults in the United States reported having a source of usual health care in 2024, with differences seen by age and sex.

Blaine Labs recalls Revitaderm and Tridergel wound care gels due to microbial contamination with Lysinibacillus fusiformis.

President Donald Trump signed an executive order to increase research and issue priority review vouchers for clinical use of psychedelics.

Funding disruptions by the Trump administration preceded decreases in HIV testing, diagnosis, prevention, and treatment among infants.

Real-world data on spesolimab have shown rapid improvement in acute flares of GPP, along with a favorable safety profile, according to a systemic review.

Superior efficacy and comparable safety was seen with DFD-29 in patients with rosacea when compared with the current first-line systemic.

Drug prices have increased overall during President Donald Trump's negotiations on "most favored nation" drug pricing.

After months of leadership changes, President Donald Trump has chosen a new candidate to lead the U.S. Centers for Disease Control and Prevention (CDC). The White House announced Thursday that Dr.